Ben Jones, vice president, Government Relations & Public Policy, McKesson Specialty Health, offers his thoughts on whether site-neutral payments for outpatient clinic visits under the Outpatient Prospective Payment System will have positive implications for community practices.
Ben Jones, vice president, Government Relations & Public Policy, McKesson Specialty Health, offers his thoughts on whether site-neutral payments for outpatient clinic visits under the Outpatient Prospective Payment System will have positive implications for community practices.
Transcript
In November, CMS finalized site-neutral payments for outpatient clinic visits under the Outpatient Prospective Payment System. Do you think this change will have positive implications for community practices?
I do. This is one more step toward parity in reimbursement that is going to address this unleveled playing field that currently exists. This is something that often times results in consolidation. The closer we drive to site of service parity, the more we’re going to remove that incentive to consolidate community practices. The 2 things that I will say is that 1: unfortunately, this is something that is tied up in court and it’s very unlikely that Congress or the administration will expand on the policy until the court rules on this actual proposal. 2: unfortunately, what they’ve done by achieving parity in this manner is essentially brining costs down to the lowest common denominator. So, if you think about parity as a disparity in payment as it exists today, hospitals are here and community practices are here. Instead of finding a way to meet in the middle, what they’ve done is just bring everybody down here.
That’s obviously in an effort to show more cost savings from the government’s perspective, but often times that puts a heavier burden on the impacted hospitals, and that’s a conversation that still needs to be had. We don’t want to be in the practice of just taking money from hospitals for money’s sake. We think that the perceived incentives should be removed or we think that this incentive to consolidate should be removed by leveling the playing field, but we don’t want to put hospitals out of business, so let’s have a conversation. Whether that means we meet in the middle or whether that means there’s a separate conversation about overhead costs that hospitals have. Unfortunately, I don’t think any of those conversations will take place until the court actually acts on this proposal.
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
VBID, Heading Into a Third Decade, Looks to Promote Personalization and Access
March 12th 2025Speakers at the 2025 Value-Based Insurance Design summit recapped the accomplishments made over the past 20 years in designing insurance benefits with value in mind and looked ahead to iterations to come.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Advancing HIV Care With Doravirine and Islatravir: Q&A With Amy Colson, MD, MPH
March 12th 2025New data from the MK-8591A-051 and MK-8591A-052 trials, both investigating the efficacy and safety of 100-mg doravirine and 0.25-mg islatravir as a once-daily 2-drug regimen for virologically suppressed people living with HIV-1, were presented today by Amy Colson, MD, MPH.
Read More
Implementation, Adherence to DoxyPEP Remains Low in At-Risk Groups
March 12th 2025Patients in Washington D.C. and San Francisco had minimal early uptake and adherence to doxycycline post-exposure prophylaxis (DoxyPEP) in studies presented at the Conference on Retroviruses and Opportunistic Infections 2025.
Read More